- Home
- HBT vs KURA Comparison
HBT vs KURA Comparison
Compare HBT & KURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HBT
- KURA
- Stock Information
- Founded
- HBT 1920
- KURA 2014
- Country
- HBT United States
- KURA United States
- Employees
- HBT N/A
- KURA N/A
- Industry
- HBT Major Banks
- KURA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- HBT Finance
- KURA Health Care
- Exchange
- HBT Nasdaq
- KURA Nasdaq
- Market Cap
- HBT 812.0M
- KURA 884.1M
- IPO Year
- HBT 2019
- KURA N/A
- Fundamental
- Price
- HBT $23.74
- KURA $11.25
- Analyst Decision
- HBT Buy
- KURA Strong Buy
- Analyst Count
- HBT 5
- KURA 13
- Target Price
- HBT $28.63
- KURA $25.40
- AVG Volume (30 Days)
- HBT 32.8K
- KURA 2.4M
- Earning Date
- HBT 10-20-2025
- KURA 11-04-2025
- Dividend Yield
- HBT 3.52%
- KURA N/A
- EPS Growth
- HBT 12.74
- KURA N/A
- EPS
- HBT 2.48
- KURA N/A
- Revenue
- HBT $233,255,000.00
- KURA $104,029,000.00
- Revenue This Year
- HBT $9.02
- KURA $68.63
- Revenue Next Year
- HBT $32.67
- KURA $141.59
- P/E Ratio
- HBT $9.61
- KURA N/A
- Revenue Growth
- HBT 6.87
- KURA N/A
- 52 Week Low
- HBT $19.46
- KURA $5.41
- 52 Week High
- HBT $27.02
- KURA $17.94
- Technical
- Relative Strength Index (RSI)
- HBT 41.94
- KURA 65.40
- Support Level
- HBT $23.24
- KURA $9.51
- Resistance Level
- HBT $24.11
- KURA $12.49
- Average True Range (ATR)
- HBT 0.61
- KURA 0.93
- MACD
- HBT -0.00
- KURA 0.07
- Stochastic Oscillator
- HBT 23.76
- KURA 66.80
About HBT HBT Financial Inc.
HBT Financial Inc provides a comprehensive suite of business, commercial, wealth management, and retail banking products and services to individuals, businesses, and municipal entities throughout Central and Northeastern Illinois and Eastern Iowa. It operates through one reportable segment: community banking.
About KURA Kura Oncology Inc.
Kura Oncology Inc is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The company's pipeline consists of small molecule drug candidates targeting cancer signaling pathways.